Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

LAMIVUDINE Synonym: 3TC Trade names: Combivir (GSK); Epivir (GSK); Trizivir (GSK) Indications: HIV progression Category: Antiretroviral; Nucleoside analog reverse transcriptase inhibitor Half-life: 5–7 hours Combivir is lamivudine and zidovudine Reactions Skin Acute generalized exanthematous pustulosis (AGEP) (1998): Aquilina C+, Arch Intern Med 158(19), 2160 (with zidovudine) Angioedema (1996): Kainer MA+, Lancet 348, 1519 Dermatitis (2000): Smith KJ+, Cutis 65, 227 Exanthems Pruritus (2000): Smith KJ+, Cutis 65, 227 Rash (sic) (9%) Urticaria (1996): Kainer MA+, Lancet 348, 1519 Hair Hair – alopecia (1994): Fong IW, Lancet 344, 1702 Nails Nails – onychocryptosis (2001): James CW+, Ann Pharmacother 35(7), 881 (with ritonavir) Nails – paronychia (1998): Zerboni R+, Lancet 351, 1256 Other Anaphylactoid reactions/Anaphylaxis (1996): Kainer MA+, Lancet 348(9040), 1519 Chills (1–10%) Gynecomastia (2001): Manfredi R+, Ann Pharmacother 35(4), 438 (with savudine) (3 cases) Hypersensitivity (2002): Winston A+, IntJSTDAIDS13(3), 213 Myalgia/Myositis/Myopathy/Myotoxicity (8%) Rhabdomyolysis (2005): Adani GL+, Am J Transplant 5(3), 634 (2002): Yahagi K+, Liver Transpl 8(12), 1198 (1997): Mendila M+, Dtsch Med Wochenschr 122(33), 1003 LAMOTRIGINE Synonyms: BW-430C; LTG Trade name: Lamictal (GSK) Indications: Epilepsy Category: Anticonvulsant; Mood stabilizer Half-life: 24 hours Clinically important, potentially hazardous interactions with: oral contraceptives Reactions LAMOTRIGINE 317 Skin Acne (1.3%) (2004): Nielsen JN+, J Clin Psychiatry 65(12), 1720 (2 cases) Acute generalized exanthematous pustulosis (AGEP) (2001): Wensween CA+, Ned Tijdschr Geneeskd 145(31), 1525 Adverse effects (sic) (2002): Hurley SC, Ann Pharmacother 36(5), 860 Angioedema (1–10%) (2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~1%) Bullous dermatitis (1997): Australian Adverse Drug Reactions Bulletin 16(1), February Diaphoresis (

318 LAMOTRIGINE (2003): Naisbitt DJ+, J Allergy Clin Immunol 111(6), 1393 (2003): Vieta E+, Actas Esp Psiquiatr 31(2), 65 (2002): Anderson GD, Epilepsia 43(Suppl 3), 53 (10–20%) (2002): Bowden CL, Expert Opin Pharmacother 3(10), 1513 (2002): Calabrese JR+, J Clin Psychiatry 63(11), 1012 (8.3%) (2002): Huang CW+, KaohsiungJMedSci18(11), 566 (2002): Hurley SC, Ann Pharmacother 36(5), 860 (2002): Labiner DM, J Clin Psychiatry 63(11), 1010 (2001): Eisenberg E+, Neurology 57, 505 (2000): Besag FM+, Seizure 9, 282 (2000): Husain AM+, South Med J 93, 335 (2000): Jurynczyk J+, Neurol Neurochir Pol (Polish) 34, 43 (2000): Messenheimer JA+, Drug Saf 22, 303 (2000): Messenheimer JA+, Epilepsia 41, 488 (2000): Parmeggiani L+, J Child Neurol 15, 15 (1999): Faught E+, Epilepsia 40, 1135 (1999): Gericke CA+, Epileptic Disord 1, 159 (1999): Guberman AH+, Epilepsia 40, 985 (1999): Matsuo F, Epilepsia 40, S30 (1998): Buzan RD+, J Clin Psychiatry 59, 87 (re-challenged) (1998): Messenheimer JA, Can J Neurol Sci 25, S14 (1997): Mackay FJ+, Epilepsia 38, 881 Raynaud’s phenomenon (2000): Sarzi-Puttini P+, Lupus 9(7), 555 Stevens–Johnson syndrome (1–10%) (2007): Hilas O+, Am J Health Syst Pharm 64(3), 273 (2007): Kocak S+, Am J Clin Dermatol 8(2), 107 (with valproic acid) (2006): Hirsch LJ+, Epilepsia 47(2), 318 (1 case) (2006): Wolf R+, Int Arch Allergy Immunol 141(3), 308 (2005): Fein JD+, NEnglJMed352(16), 1696 (2005): Mockenhaupt M+, Neurology 64(7), 1134 (2003): Feliciani C+, Int J Immunopathol Pharmacol 16(1), 89 (2002): Bowden CL, Expert Opin Pharmacother 3(10), 1513 (2002): Calabrese JR+, J Clin Psychiatry 63(11), 1012 (1 case) (2002): Huang CW+, KaohsiungJMedSci18(11), 566 (2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~10%) (2000): Popescu C, Bucharest, Romania (from Internet) (observation) (2000): Yalcin B+, JAmAcadDermatol43, 898 (with valproic acid) (1999): Bocquet H+, Ann Dermatol Venereol (French) 126, 46 (1999): Borowitz SM, Pediatric Pharmacotherapy 5, 3 (1999): Guberman AH+, Epilepsia 40, 985 (1999): Rzany B+, Lancet 353, 2190 (1998): Drugs and Therapy Perspectives 11, 11 (1998): Messenheimer J+, Drug Saf 18(4), 281 (1998): Schlienger RG+, Epilepsia 39, S22 (1998): Zachariae CO+, Ugeskr Laeger (Danish) 160, 6656 (1997): Australian Adverse Drug Reactions Bulletin 16(1), February (1997): Knowles S+, Curr Opin Pediatr 9(4), 388 (1997): Mackay FJ+, Epilepsia 38, 881 (1997): Sachs B+, Dermatology 195, 60 (1996): Dooley J+, Neurology 46, 240 (7%) (1995): Campistol J+, Rev Neurol (Spanish) 23, 1236 (1995): Duval X+, Lancet 345, 1301 Toxic epidermal necrolysis (2006): Varghese SP+, Pharmacotherapy 26(5), 699 (2005): Mansouri P+, Arch Dermatol 141(6), 788 (with carbamazepine) (2005): Rodriguez-Blanco I+, Actas Dermosifiliogr 96(2), 116 (2004): Haefliger IO+, Klin Monatsbl Augenheilkd 221(5), 395 (2004): Hashim N+, Acta Derm Venereol 84(1), 90 (with valproic acid) (2004): Sladden M+, Aust Fam Physician 33(10), 829 (2003): Clennett S+, J Wound Care 12(4), 151 (2003): Feliciani C+, Int J Immunopathol Pharmacol 16(1), 89 (2003): Mayorga C+, Ann Allergy Asthma Immunol 91(1), 86 (2003): Sogut A+, Acta Neurol Belg 103(2), 95 (2002): Wirtzer A, Sherman Oaks, CA (from Internet) (observation) (2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~1%) (2001): Wensween CA+, Ned Tijdschr Geneeskd 145(31), 1525 (2000): Bhushan M+, Clin Exp Dermatol 25, 349 (2000): Fernandez-Calvo C+, Rev Neurol 31(12), 1162 (1999): Actas Dermosifiliogr (Spanish) 90, 612 (1999): Bocquet H+, Ann Dermatol Venereol (French) 126, 46 (1999): Borowitz SM, Pediatric Pharmacotherapy 5, 3 (1999): Rzany B+, Lancet 353, 2190 (1998): Drugs and Therapy Perspectives 11, 11 (1998): Page RL+, Pharmacotherapy 18, 392 (fatal) (1998): Schlienger RG+, Epilepsia 39, S22 (1998): Zachariae CO+, Ugeskr Laeger (Danish) 160, 6656 (1997): Australian Adverse Drug Reactions Bulletin 16(1), February (1997): Chaffin JJ+, Ann Pharmacother 31, 720 (suspected) (1997): Fogh K+, Seizure 6, 63 (1997): Knowles S+, Curr Opin Pediatr 9(4), 388 (1997): Vukelic D+, Dermatology 195, 307 (1996): Sachs B+, Lancet 348, 1597 (1996): Sullivan JR+, Australas J Dermatol 37, 208 (1996): Wadelius M+, Lancet 348, 1041 (1995): Duval X+, Lancet 345, 1301 (1995): Sterker M+, Int J Clin Pharmacol Ther 33, 595 Urticaria (

LAMIVUDINE<br />

Synonym: 3TC<br />

Trade names: Combivir (GSK); Epivir (GSK); Trizivir (GSK)<br />

Indications: HIV progression<br />

Category: Antiretroviral; Nucleoside analog reverse<br />

transcriptase inhibitor<br />

Half-life: 5–7 hours<br />

Combivir is lamivudine <strong>and</strong> zidovudine<br />

Reactions<br />

Skin<br />

Acute generalized exanthematous pustulosis (AGEP)<br />

(1998): Aquilina C+, Arch Intern Med 158(19), 2160 (with<br />

zidovudine)<br />

Angioedema<br />

(1996): Kainer MA+, Lancet 348, 1519<br />

Dermatitis<br />

(2000): Smith KJ+, Cutis 65, 227<br />

Exanthems<br />

Pruritus<br />

(2000): Smith KJ+, Cutis 65, 227<br />

Rash (sic) (9%)<br />

Urticaria<br />

(1996): Kainer MA+, Lancet 348, 1519<br />

Hair<br />

Hair – alopecia<br />

(1994): Fong IW, Lancet 344, 1702<br />

Nails<br />

Nails – onychocryptosis<br />

(2001): James CW+, Ann Pharmacother 35(7), 881 (with<br />

ritonavir)<br />

Nails – paronychia<br />

(1998): Zerboni R+, Lancet 351, 1256<br />

Other<br />

Anaphylactoid reactions/Anaphylaxis<br />

(1996): Kainer MA+, Lancet 348(9040), 1519<br />

Chills (1–10%)<br />

Gynecomastia<br />

(2001): Manfredi R+, Ann Pharmacother 35(4), 438 (with<br />

savudine) (3 cases)<br />

Hypersensitivity<br />

(2002): Winston A+, IntJSTDAIDS13(3), 213<br />

Myalgia/Myositis/Myopathy/Myotoxicity (8%)<br />

Rhabdomyolysis<br />

(2005): Adani GL+, Am J Transplant 5(3), 634<br />

(2002): Yahagi K+, Liver Transpl 8(12), 1198<br />

(1997): Mendila M+, Dtsch Med Wochenschr 122(33), 1003<br />

LAMOTRIGINE<br />

Synonyms: BW-430C; LTG<br />

Trade name: Lamictal (GSK)<br />

Indications: Epilepsy<br />

Category: Anticonvulsant; Mood stabilizer<br />

Half-life: 24 hours<br />

Clinically important, potentially hazardous interactions<br />

with: oral contraceptives<br />

Reactions<br />

LAMOTRIGINE 317<br />

Skin<br />

Acne (1.3%)<br />

(2004): Nielsen JN+, J Clin Psychiatry 65(12), 1720 (2 cases)<br />

Acute generalized exanthematous pustulosis (AGEP)<br />

(2001): Wensween CA+, Ned Tijdschr Geneeskd 145(31), 1525<br />

Adverse effects (sic)<br />

(2002): Hurley SC, Ann Pharmacother 36(5), 860<br />

Angioedema (1–10%)<br />

(2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~1%)<br />

Bullous dermatitis<br />

(1997): Australian Adverse <strong>Drug</strong> Reactions Bulletin 16(1), February<br />

Diaphoresis (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!